Zahedan Journal of Research in Medical Sciences

Published by: Kowsar

Effects of Isradipine on Induced-Parkinson’s Disease in Rats

Gholamreza Komeili 1 , * and Farzaneh Farajian-Mashhadi 2
Authors Information
1 Department of Physiology, Faculty of Medicine, Zahedan University of Medical Sciences, Zahedan, IR Iran
2 Department of Pharmacology, Faculty of Medicine, Zahedan University of Medical Sciences, Zahedan, IR Iran
Article information
  • Zahedan Journal of Research in Medical Sciences: April 30, 2016, 18 (4); e6444
  • Published Online: April 26, 2016
  • Article Type: Short Communication
  • Received: January 17, 2015
  • Accepted: November 16, 2015
  • DOI: 10.17795/zjrms-6444

To Cite: Komeili G, Farajian-Mashhadi F. Effects of Isradipine on Induced-Parkinson’s Disease in Rats, Zahedan J Res Med Sci. 2016 ; 18(4):e6444. doi: 10.17795/zjrms-6444.

Copyright © 2016, Zahedan University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
  • 1. Gorbatyuk OS, Li S, Sullivan LF, Chen W, Kondrikova G, Manfredsson FP, et al. The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease. Proc Natl Acad Sci U S A. 2008; 105(2): 763-8[DOI][PubMed]
  • 2. Gorbatyuk MS, Shabashvili A, Chen W, Meyers C, Sullivan LF, Salganik M, et al. Glucose regulated protein 78 diminishes alpha-synuclein neurotoxicity in a rat model of Parkinson disease. Mol Ther. 2012; 20(7): 1327-37[DOI][PubMed]
  • 3. Surmeier DJ, Guzman JN, Sanchez-Padilla J, Schumacker PT. The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson's disease. Neuroscience. 2011; 198: 221-31[DOI][PubMed]
  • 4. Bekris LM, Mata IF, Zabetian CP. The genetics of Parkinson disease. J Geriatr Psychiatry Neurol. 2010; 23(4): 228-42[DOI][PubMed]
  • 5. Fernandez HH. Updates in the medical management of Parkinson disease. Cleve Clin J Med. 2012; 79(1): 28-35[DOI][PubMed]
  • 6. Ilijic E, Guzman JN, Surmeier DJ. The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease. Neurobiol Dis. 2011; 43(2): 364-71[DOI][PubMed]
  • 7. Surmeier DJ. Calcium, ageing, and neuronal vulnerability in Parkinson's disease. Lancet Neurol. 2007; 6(10): 933-8[DOI][PubMed]
  • 8. Pasternak B, Svanstrom H, Nielsen NM, Fugger L, Melbye M, Hviid A. Use of calcium channel blockers and Parkinson's disease. Am J Epidemiol. 2012; 175(7): 627-35[DOI][PubMed]
  • 9. Ton TG, Heckbert SR, Longstreth WJ, Rossing MA, Kukull WA, Franklin GM, et al. Calcium channel blockers and beta-blockers in relation to Parkinson's disease. Parkinsonism Relat Disord. 2007; 13(3): 165-9[DOI][PubMed]
  • 10. Johnson BA, Ait-Daoud N, Wells LT. Effects of isradipine, a dihydropyridine-class calcium channel antagonist, on D-methamphetamine-induced cognitive and physiological changes in humans. Neuropsychopharmacology. 2000; 22(5): 504-12[DOI][PubMed]
  • 11. Sautter J, Kupsch A, Earl CD, Oertel WH. Degeneration of pre-labelled nigral neurons induced by intrastriatal 6-hydroxydopamine in the rat: behavioural and biochemical changes and pretreatment with the calcium-entry blocker nimodipine. Exp Brain Res. 1997; 117(1): 111-9[PubMed]
  • 12. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. 2007; 12
  • 13. Sarkaki A, Alavian SM, Mansouri SMT. A study on straital local electrical potential changes in animal model of parkinson`s disease. Iran J Pharm Res. 2004; 3(1): 80
  • 14. Morpurgo C. Effects of antiparkinson drugs on a phenothiazine-induced catatonic reaction. Arch Int Pharmacodyn Ther. 1962; 137: 84-90[PubMed]
  • 15. Schuster S, Doudnikoff E, Rylander D, Berthet A, Aubert I, Ittrich C, et al. Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-3,4-dihydroxyphenylalanine-induced dyskinesia. Biol Psychiatry. 2009; 65(6): 518-26[DOI][PubMed]
  • 16. Kupsch A, Gerlach M, Pupeter SC, Sautter J, Dirr A, Arnold G, et al. Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice. Neuroreport. 1995; 6(4): 621-5[PubMed]
  • 17. Munoz A, Carlsson T, Tronci E, Kirik D, Bjorklund A, Carta M. Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model. Exp Neurol. 2009; 219(1): 298-307[DOI][PubMed]
  • 18. Tai CH, Yang YC, Pan MK, Huang CS, Kuo CC. Modulation of subthalamic T-type Ca(2+) channels remedies locomotor deficits in a rat model of Parkinson disease. J Clin Invest. 2011; 121(8): 3289-305[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments